Please assess the completion status of the following clinical trial:

Trial Title: PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: ≥18 years and ≤60 years~* At least one family member should have a clinical diagnosis of dilated cardiomyopathy (LVEF\<45% and LVEDD\>112%)and should not be considered as the burn-out phase of another cardiomyopathy (such as HCM, ARVC). LV noncompaction may co-exist with DCM in this patient.NB:in a patient with a mutation in LMNA gene, LVEDD may be normal whereas EF is markedly reduced, so that only a reduced LVEF is mandatory(LVEF\<45%).~* Carriers of the mutation that has been identified in the family as associated with DCM, and who have received appropriate genetic counselling before and after the announcement of the genetic result. The mutation within the family should be considered as disease-causing.~* No obvious DCM as assessed by diagnostic criteria indicated elsewhere on echocardiography (WHO \& Mestroni et al. 1999 and Mahon et al. 2005: references 3 and 9): LVEF \<45% and enlarged LVEDD (\>112% of predicted value according to age,BSA).~* Presence of minor LV abnormality:~  * isolated LVEDD \> 112% (Henry Formula)~ * or reduced systolic dysfunction: 45% \< LVEF \< 55%, as assessed on echocardiography.~* Able to provide informed consent, and signed informed consent.~* Able to understand and accept the study constraints~* For some European countries (such as France and Spain): participants (by themselves) should have medical health care coverage to be included in a research study~Exclusion Criteria:~* Other disease or factor that can cause minor LV abnormalities, such as cardiotoxic treatment or significant blood hypertension (with uncontrolled blood pressure or significant hypertrophy on echocardiography).~* Contraindication to ACE inhibitor~* Participants who are already treated with ACE inhibitor, sartan or aldosterone receptor antagonists (for various reason such as arterial hypertension) can not be included in this study, unless they have been off these drugs for a period of 6 weeks before inclusion.~* Impaired renal function: estimated Glomerular Filtration Rate (eGFR), using MDRD formula, \< 60 ml/mn/1.73m2.~* Baseline serum potassium \>5.5 mmol/L.~* Pregnant, parturient or breastfeeding woman or woman of childbearing potential not under effective contraception or planned pregnancy.~* Participation in another therapeutic trial in the previous 3 months~* Participants treated with lithium~* Participant under legal guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- perindopril (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): same form, administration, posology, frequency and duration as perindopril

Based on this trial design, predict the completion outcome and termination type (if applicable).